Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of <= 6 brain metastases: a multi-institutional phase II trial Article

cited authors

  • McHaffie, Derek R; Chabot, Pierre; Dagnault, Anne; Suh, John H; Fortin, Marie-Andree; Chang, Eric; Timmerman, Robert; Souhami, Luis; Grecula, John; Nabid, Abdenour; Schultz, Chris; Werner-Wasik, Maria; Gaspar, Laurie E; Brachman, David; Mody, Tarak; Mehta, Minesh P

fiu authors

publication date

  • November 1, 2011

keywords

  • Brain metastases
  • Clinical Neurology
  • DRUG
  • Life Sciences & Biomedicine
  • Motexafin gadolinium
  • Neurosciences & Neurology
  • Oncology
  • RADIOTHERAPY
  • RIBONUCLEOTIDE REDUCTASE
  • SURVIVAL
  • Science & Technology
  • Stereotactic radiosurgery
  • TEXAPHYRIN
  • TUMORS

Digital Object Identifier (DOI)

start page

  • 301

issue

  • 2